What is the market's earnings forecast for Enhabit next quarter?

What does Enhabit do and what are its main business segments?

What guidance did Enhabit's management provide for the next earnings period?

What factors drove the changes in Enhabit's revenue and profit?

What were the key takeaways from Enhabit's earnings call?

Did Enhabit beat or miss consensus estimates last quarter?

What is Enhabit's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Enhabit year over year?

- **Revenue Growth**: Home Health admissions +3.6% YoY, Hospice revenue +20% YoY driven by de novo openings and sales expansion.
- **Cost Efficiency**: G&A expenses down 9.1% of revenue, net debt reduced $15.5M QoQ, leverage ratio 3.9x.
- **Strategic Initiatives**: Visits per episode pilot reduces costs, 10 de novo openings on track for 2025.
- **Operational Resilience**: Recovered 120% of disrupted census levels, Hospice LOS stable at 101 days, mitigating CMS rule risks.

**【CEO Opening Remarks】**
- Home Health admissions grew 3.6% YoY, census up 3.7% YoY. Non-Medicare revenue per visit increased 2.8% YoY.
- Recovered 120% of pre-renegotiation census levels with a national payer by late Q3.
- Hospice admissions grew 1.4% YoY, census up 12.6% YoY. Added 21 direct sales team members (+11% YoY).
- Launched 2 de novo locations in Q3, bringing total to 6 YTD, on track for 10 by year-end.
- Piloted 'visits per episode' optimization in 11 branches, reducing visits from 15 to 13, with full rollout expected by end of Q4.

**【CFO Financial Commentary】**
- Consolidated net revenue: $263.6M (+3.9% YoY). Adjusted EBITDA: $27M (+10.2% YoY), margin 10.2% vs 9.7% YoY.
- Home Health revenue flat YoY (-0.2%), impacted by payer disruption. Hospice revenue up 20% YoY, EBITDA up 72% YoY.
- G&A expenses improved sequentially to 9.1% of revenue ($24.1M), down $2.3M QoQ. Reduced net debt by $15.5M QoQ, leverage ratio 3.9x vs 4.8x YoY.
- Updated FY25 guidance: Revenue $1.058B-$1.063B, EBITDA $106M-$109M, free cash flow $53M-$61M.

**【Q&A Highlights】**
- Payer contracts typically 3-year terms; 2025 renegotiations achieved rate increases without census disruption.
- G&A savings from headcount reductions and in-sourcing, with $1M-$1.5M sequential improvement.
- Hospice seasonal trends: Q4 2024 saw 101-day average LOS, 2025 expects similar volatility.
- Labor market: Nursing/therapy applicant pools improving, wage inflation ~3% YoY.

Enhabit, Inc. (EHAB) Q3 2025 Earnings Call Transcript

- **CMS Headwinds**: 2026 proposed 6.4% home health rate cut requires aggressive VPE optimization, with pilot expected to yield $5-8M savings per 0.5 VPE reduction.
- **Financial Strength**: Q2 revenue $266.1M (+2.1% YoY), EBITDA $26.9M (+6.7% YoY). Debt reduced $50M YTD, leverage down to 4.3x.
- **Segment Growth**: Hospice census +12.3% YoY, home health Medicare census stabilizing. 10 new locations opened in 2025.
- **Leadership Transition**: CEO Barb Jacobsmeyer to step down in July 2026, setting stage for new strategic chapter.


**【CEO Opening Remarks】**
- CMS' 2026 proposed home health rule includes a 6.4% rate cut, which Enhabit views as flawed and unsustainable. The company is actively piloting advanced visit per episode (VPE) management to mitigate the impact.
- Home health admissions grew 1.3% YoY (2% normalized for branch closures), with Medicare census stabilizing (+0.5% YoY). Non-Medicare admissions rose 5.2% driven by payer innovation contracts.
- Hospice segment continues strong growth: admissions +8.7% YoY (10% normalized), census +12.3% YoY. 11 branches closed/consolidated YTD, with 10 new locations opened in 2025.
- CEO Barb Jacobsmeyer announced her planned departure in July 2026, citing the need for fresh leadership to drive next-level growth.

**【CFO Financial Commentary】**
- Q2 2025 consolidated net service revenue: $266.1M (+2.1% YoY), with adjusted EBITDA of $26.9M (+6.7% YoY). Home health EBITDA margin: 19.1%, hospice: 23.3%.
- Debt reduced by $50M YTD through prepayments, lowering annual interest expense by $10M. Net debt/EBITDA leverage improved to 4.3x (from 5.1x YoY).
- Full year 2025 guidance: Revenue $1.06-1.07B, adjusted EBITDA $100-108M, free cash flow $47-57M.

**【Q&A Highlights】**
- **CMS Rule Mitigation**: VPE pilot expected to generate $5-8M annual savings per 0.5 VPE reduction. Full implementation could offset 2026 rate cuts.
- **Payer Contract Success**: Renegotiated national payer contract with +low double-digit rate increase, regaining 76% of lost census within 2 weeks.
- **Volume Trends**: Medicare fee-for-service decline rate cut in half (3.4% YoY vs. 14.1% in 2024). Hospice ADC growth sustained across all regions.
- **Strategic Priorities**: Focus on cost control, payer mix optimization, and disciplined M&A after further deleveraging.


Enhabit (EHAB)-7 Aug 25-2025 Q2 Earnings call transcript

- **Home Health Recovery**: Medicare ADC up 1.5% QoQ, reversing prior declines. Non-Medicare revenue per visit +7.6% YoY. 
- **Hospice Momentum**: 12.3% YoY census growth, 310bps improvement in conversion rate. 13 de novo projects in pipeline. 
- **Cost Efficiency**: $1.5M annual coding savings, 3.1% QoQ drop in Medicare cost per day. 
- **Financial Strength**: 4.4x leverage ratio (below covenant), $17M free cash flow. 
- **Growth Drivers**: Payer innovation contracts (44% of non-Medicare visits), MetaLogix Pulse tool utilization, and 16% RN capacity growth.

**【CEO Opening Remarks】**
- **Home Health Performance**: Sequential admissions grew 8.1%, with non-Medicare visits under payer innovation contracts rising to 44% (from 38% in Q1 2024). Non-Medicare revenue per visit increased 7.6% YoY. Medicare ADC improved 1.5% sequentially, reversing prior declines. Total home health census exited March 9.8% higher than January. 
- **Hospice Growth**: Total admissions up 8% YoY (5.2% same-store), census up 12.3% (10.6% same-store). Conversion rate improved 310bps to 79%. 13 de novo projects underway. 
- **Cost Structure**: $1.5M annualized savings from outsourced coding. 2 internal apps piloted to improve clinician communication and referral processing. 
- **Employee Engagement**: Survey results above healthcare benchmarks, driven by meaningful work and collaboration. 

**【CFO Financial Highlights】**
- **Consolidated Results**: Q1 net revenue $259.9M (-1.0% YoY), adjusted EBITDA $26.6M (+5.1% YoY). EBITDA margin 10.2% (vs 9.6% prior year). 
- **Home Health**: Revenue $200.6M, EBITDA $38.3M (+7.9% QoQ). Gross margin 48.5% (up 110bps QoQ). Medicare cost per day down 3.1% QoQ. 
- **Hospice**: Revenue $59.3M (+20.5% YoY), EBITDA $15.0M (+12.8% QoQ). Unit revenue per day stable after reversing $1M Medicare cap liability. 
- **Balance Sheet**: Reduced debt by $25M, ending with $40M cash and 4.4x leverage ratio (vs covenant of 4.5x). Free cash flow $17M (63.5% conversion). 

**【Key Q&A Takeaways】**
- **Non-Medicare Growth**: 82% of admission growth driven by payer innovation contracts. Field teams balancing Medicare/non-Medicare mix. 
- **Labor Costs**: Expect 2-3% salary inflation, with 4% RN capacity growth Q4-Q1. 
- **Hospice Sustainability**: 16% RN capacity growth vs 12.3% census growth, giving confidence in continued growth. 
- **Contract Renewals**: 43 contracts in pipeline, some with escalators tied to quality metrics. 
- **Research Rate**: Focused on census growth over research, with early institutional admissions offsetting lower research potential.

Enhabit (EHAB)-8 May 25-2025 Q1 Earnings call transcript

- **Home Health Recovery**: Non-Medicare admissions up 10.7% YoY, census growth 5.4% (excl. hurricanes). Payor innovation contracts now 48% of non-Medicare visits.
- **Hospice Momentum**: Q4 same-store census +7%, 2025 Q1-February growth continues. 
- **Cost Savings**: $1.5M annual coding outsourcing and $1M EBITDA from branch closures.
- **2025 Outlook**: 7% revenue growth, home health ADC +4-5%, hospice ADC +7-8.5%. Wage inflation offset by productivity.

**【CEO Summary Section】**
- **Home Health Performance**: Non-Medicare admissions grew 10.7% YoY, driving total admissions up 1.8%. Excluding hurricane impacts, admission growth would have been 5.4%. Payor innovation contracts now account for 48% of non-Medicare visits, with non-Medicare revenue per visit up 5.7% YoY. January-February 2025 census grew 7.2% sequentially.
- **Hospice Growth**: Q4 same-store census increased 7%, with full-year cost per day up 2.6%. January-February 2025 trends show continued census growth. 
- **Cost Optimization**: Closing 7 branches and outsourcing coding will save $1.5M in 2025 and $1.5M annually thereafter.

**【CFO Financial Commentary】**
- **Q4 Results**: Net revenue $258.2M (-0.9% YoY), adjusted EBITDA $25.1M. Hospice revenue grew 9.9% QoQ, driven by new CMS rates and cap accrual benefits.
- **2025 Guidance**: Net service revenue $1.05B-$1.08B (+7%), adjusted EBITDA $101M-$107M. Home Health ADC growth 4-5%, Hospice ADC growth 7-8.5%. Wage inflation (~3%) partially offset by productivity gains.

**【Q&A Highlights】**
- **2025 Growth Drivers**: Hospice case management model and home health payor mix optimization. 
- **Hospice Revenue Breakdown**: $1.4M cap accrual benefit and CMS rate increases contributed to Q4 growth.

EHAB

EHAB fundamentals

Earnings Call

You can ask Aime